PSMA-PET molecular imaging more often triggers changes in salvage radiation treatment compared with usual care. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) imaging ...

MELBOURNE, Australia and INDIANAPOLIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces a research collaboration with University ...

Researchers presented clinical study results on the dual-tracer PET imaging technique at the European urology conference with peer-reviewed publication forthcoming.

But does it cost too much?

Study findings support PSMA-PET as a first-line approach for the primary staging of intermediate- to high-risk prostate cancer. In head-to-head comparisons, prostate-specific membrane antigen positron ...

A molecular imaging tool developed by researchers at the University of California's two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer ...

Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

Telix Pharmaceuticals (NASDAQ:TLX) outlined its commercial imaging franchise, regulatory plans for two radiodiagnostic ...